The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

In this group of patients the M 1 antagonism on cholinergic pathways and the spasmolytic effect on the sphincter of Oddi may be of importance. Most patients included in the trial had mild to ...

Muscarinic receptors are involved with neurotransmission ... Most drugs developed to treat schizophrenia to date target dopamine pathways. The hope is that NBI-1117568 will have a two-pronged ...